CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by Sanofi
Mechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes
Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.